-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group’s Pentoxifylline Injection and Ipratropium Bromide Solution for Inhalation Have Been Approved
Category:
发布时间：2022-10-11
【概要描述】
Recently, two products—pentoxifylline injection (5 mL: 0.1 g) and ipratropium bromide solution for inhalation (2 mL: 0.5 mg and 2 mL: 0.25 mg)—developed by Shijiazhuang Sihua Pharmaceutical Group, each available in three specifications, were simultaneously granted drug registration certificates by the National Medical Products Administration. These products are also deemed to have passed the evaluation of quality and therapeutic equivalence for generic drugs, with pentoxifylline injection (5 mL: 0.1 g) becoming the first such product from a domestic pharmaceutical company to receive this designation.
In the golden autumn season, Shijiazhuang No.4 Pharmaceutical has reaped abundant achievements in scientific research and innovation. Recently, two products—pentoxifylline injection (5 mL: 0.1 g) and ipratropium bromide solution for inhalation (2 mL: 0.5 mg and 2 mL: 0.25 mg)—developed by Shijiazhuang No.4 Pharmaceutical Group, each available in three specifications, were simultaneously granted drug registration certificates by the National Medical Products Administration. These products are also deemed to have passed the evaluation of quality and therapeutic equivalence for generic drugs, with pentoxifylline injection (5 mL: 0.1 g) becoming the first such product from a domestic pharmaceutical company to receive this designation.
According to reports, pentoxifylline injection is primarily used to treat peripheral arterial disease and inner-ear circulatory disorders, while ipratropium bromide solution for inhalation is mainly indicated for the relief of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis, emphysema, and asthma.
In recent years, Shijiazhuang Sihua Pharmaceutical Group has increasingly demonstrated its innovative strengths. Since the beginning of this year, the company has obtained 35 product approvals, including 26 for finished dosage forms. To date, a total of 31 drug varieties encompassing 41 specifications have either passed or been deemed to have passed the National Evaluation of Quality and Therapeutic Equivalence for Generic Drugs. The group’s efficiency and volume of specialized generic drug R&D rank among the top in the national pharmaceutical industry, with innovation effectively driving the continuous optimization and upgrading of the company’s product portfolio and value chain.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091